Devyser and
"We are very excited to enter into this agreement. Up to now, our products have not been available in the large Brazilian market, and we are highly optimistic about future sales in the country, which has the second-highest number of transplanted organs globally. The agreement provides laboratories in
In
The information was submitted for publication, through the agency of the contact persons below, on
For more information, please contact:
Fredrik Alpsten, CEO
Email: fredrik.alpsten@devyser.com
Telephone: +46 70 667 31 06
Email: sabina.berlin@devyser.com
Telephone: +46 73 951 95 06
About Devyser
Devyser develops, manufactures, and sells diagnostic solutions and analysis services to clinical laboratories in more than 50 countries. Our products are used for advanced genetic testing in the hereditary disease, oncology, and transplant fields, to enable targeted cancer treatment, the diagnosis of many genetic diseases, and transplant patient follow-up. Devyser's products, and unique, patented solution requiring only one test tube, simplify genetic testing processes, improve sample throughput, minimize hands-on time, and deliver rapid results. Our goal is for every patient to receive a correct diagnosis in the shortest possible time.
Devyser was founded in 2004 and is based in
Devyser's shares are listed on the Nasdaq First North Premier Growth Market Stockholm (ticker: DVYSR). The company's Certified Adviser is
For more information, visit www.devyser.com.
https://news.cision.com/devyser-diagnostics-ab/r/devyser-and-thermo-fisher-scientific-expand-the-collaboration-for-post-transplant-ngs-products-by-ad,c3830273
(c) 2023 Cision. All rights reserved., source